Reference number : 276-2008-2009-Q3-00114, amendment number : , agreement type : C, recipient legal name : ImmunoVaccine Technologies Inc.|ImmunoVaccine Technologies Inc., recipient country : CA, recipient province : NS, recipient city : Halifax|Halifax, recipient postal code : B3J 3R1, program name english : Atlantic Innovation Fund (AIF) - II, program name french : Fonds d'innovation de l'Atlantique (FIA) - II, program purpose english : nan, program purpose french : nan, agreement title english : 191977, agreement title french : 191977, agreement number : 191977, agreement value : 3000000.0, agreement start date : 2008-10-06, agreement end date : 2011-03-31, description english : Evaluate Novel Adjuvant Systems in VacciMax, description french : Évaluer le nouvel adjuvant dans VacciMax, expected results english : nan, expected results french : nan, additional information english : The assistance type is Conditionally Repayable Contribution., additional information french : Le type d'aide est Contribution à remboursement conditionnel., owner organization : acoa-apeca, owner organization title : Atlantic Canada Opportunities Agency | Agence de promotion économique du Canada atlantique